Furoscix (Furosemide) Patent Expiration, LOE Window & CMS Spending

Furoscix (Furosemide) by Scpharmaceuticals A Wholly Owned Sub Of Mannkind: FDA Orange Book LOE 2040-01-30, 6 AB generics, $30.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorScpharmaceuticals A Wholly Owned Sub Of Mannkind
FDA Application & PathwayN209988 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-01-30
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$30.1M
2024 Medicare Part D Spend$27.2M
2024 Medicaid Spend$2.9M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.3% 2-yr change)